Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group Inc. has demonstrated a substantial increase in operating margin expansion, now projected to exceed 16%, reflecting strong financial performance and operational efficiency. The company is poised for growth, with anticipated new product launches and accelerated adoption rates in heart and lung transplants, alongside a robust international market presence that bodes well for future revenues. Additionally, an impressive projected 35.2% year-over-year increase in US organ transplant volume and a 40.5% rise in US sales for Q4 positions TransMedics favorably in the competitive landscape for organ preservation technology.

Bears say

TransMedics Group Inc. reported a sequential decline in aviation metrics for Q3, indicating a concerning trend in daily flights and flight hours that could suggest diminishing operational activity and efficiency. The company faced risks related to disappointing adoption of its Organ Care System, intensified competition, and potential regulatory challenges, all of which could adversely affect future growth and market presence. Furthermore, despite revenue growth of 33.1% for product revenues and 30.9% for service revenues, the slight miss against consensus forecasts and lower gross margins of 58.8% raised flags about profitability and overall commercialization effectiveness, contributing to a negative outlook on the stock.

TMDX has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 8 analysts, TMDX has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $144.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $144.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.